The National Institute for Health and Care Excellence (NICE) has recommended the use of teduglutide for the treatment of people with short bowel syndrome (SBS). In a draft guidance published on June 1 ...

When parts of the small intestine are diseased or die, the treatment can involve surgically removing the affected tissue. Although lifesaving, the procedure—referred to as a radical small bowel ...

SATB2 deficiency confers small intestinal (ileal) properties on colon cells. Green fluorescent marker bound to cholesterol (top row) and glucose (bottom row) shows absorption of nutrients in: a) Ileal ...

Data presented at annual Digestive Disease Week Congress Drug achieves increase in absolute intestinal absorption Shares up nearly 14 percent June 3 (Reuters) - NPS Pharmaceuticals presented new ...

FDA has approved a new drug to treat adults with short bowel syndrome who need additional nutrition from intravenous feeding, according to a news release. Gattex (teduglutide) is an injection ...

This infographic summarizes the main aspects of this longitudinal study—the first study to analyze the changes caused by glucagon-like peptide-2 (GLP-2) analogs to the intestinal environment in ...

Researchers from Opko Health Inc. and Entera Bio Ltd. recently presented preclinical pharmacokinetic data on OPK-8801003, an oral GLP-2 analogue developed for the treatment of short bowel syndrome.

Short bowel syndrome is a complex group of diseases caused by the loss (or loss of function) of part of the small and/or large intestine. Patients with short bowel syndrome can’t absorb sufficient ...

Researchers from Japan discover that glucagon-like peptide-2 (GLP-2) analogs can deeply and beneficially reshape the intestinal environment. Short bowel syndrome (SBS) represents one of the most ...

In pediatric patients with short-bowel syndrome on total parenteral nutrition, catheter salvage therapy demonstrated positive outcomes and was effective for central line-associated bloodstream ...

RALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today ...